skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

ジェネリック医薬品、バイオシミラーの情報源として

Generics_Bulletin2

日本国内では2020年9月までにジェネリック医薬品の使用割合を80%にする目標を挙げています。このような中、Generics Bulletinはグローバルな専門アナリスト&ジャーナリストの広範なネットワークを駆使して、世界中の市場動向を追跡することで、貴重なニュースを提供しています。また、市場プレーヤーのトップエグゼクティブやオピニオンリーダーのインタビューなども定期的に掲載しています。

深い専門性と具体的なデータに基づいたニュースレポートは、世界の大手ジェネリック医薬品メーカーの戦略を明らかにし、その計画、ポートフォリオ、業績を分析&報告します。

Generics Bulletinでは以下のトピックをカバーしています。

  • 規制・コンプライアンスの変更
  • 法規制の進展
  • 競合製品の開発
  • 合併・買収活動
  • 新製品の発売
  • マーケティングの課題
  • 広告戦略など

このサービスの特徴

無料の最新記事&レポート

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Glenmark Debuts Favipiravir For COVID-19 In India

    Glenmark has received the go-ahead in India for and launched its low-priced favipiravir product for mild to moderate COVID-19 under an accelerated approval process.

    Topic Coronavirus Drug Review

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Dr Reddys Joins Remdesivir Licensees

    Dr Reddy’s has become the latest firm to strike a licensing deal with Gilead for its remdesivir potential treatment for COVID-19.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    WHO Launches COVID-19 Technology Access Pool

    C-TAP, the voluntary initiative aimed at making vaccines, tests, treatments and other health technologies to fight COVID-19 accessible to all, has been launched by the WHO, in partnership with Costa Rica.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Teva, Sandoz And Accord Take COVID-19 Action

    While Teva has helped to mitigate a Canadian shortage of salbutamol inhalers, Accord has struck a deal with the UK government to supply hydroxychloroquine. Sandoz is bolstering its inventory to meet demand and Apotex is donating critical medicines, while MedPharm’s new testing model will screen drugs for therapeutic effectiveness and Beximco is focusing on manufacturing hydroxychloroquine, favipiravir and ivermectin.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Hikma Outlines Strategy For Coping With COVID-19 Demand

    Hikma Outlines Strategy For Coping With COVID-19 Demand

    As Hikma launches propofol vials in three presentations in the US to address a local shortage, CEO Siggi Olafsson explains how the company is more broadly keeping on top of the higher demand generated by the coronavirus pandemic.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Teva, Sandoz And Accord Take COVID-19 Action

    While Teva has helped to mitigate a Canadian shortage of salbutamol inhalers, Accord has struck a deal with the UK government to supply hydroxychloroquine. Sandoz is bolstering its inventory to meet demand and Apotex is donating critical medicines, while MedPharm’s new testing model will screen drugs for therapeutic effectiveness and Beximco is focusing on manufacturing hydroxychloroquine, favipiravir and ivermectin.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    WHO Launches COVID-19 Technology Access Pool

    WHO Launches COVID-19 Technology Access Pool

    C-TAP, the voluntary initiative aimed at making vaccines, tests, treatments and other health technologies to fight COVID-19 accessible to all, has been launched by the WHO, in partnership with Costa Rica.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Celltrion Sets Out Plans To Trial Coronavirus Treatments

    In an exclusive interview with Generics Bulletin, Celltrion Healthcare’s UK commercial director, Matt Eddleston, has set out the firm’s plans to roll out an antibody test and trial two antiviral treatments for COVID-19. Meanwhile, the company’s recently-launched subcutaneous version of biosimilar infliximab, Remsima SC, is helping to free up hospital space in the UK by allowing treatment to be moved out of that setting as the coronavirus pandemic progresses.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Biosimilars Conference Coverage

    Biosimilars Conference Coverage

    Industry analysts from Generics Bulletin are bringing you free insights from their comprehensive biosimilars coverage. Obtain critical industry information covering new biosimilars launches, company strategies, and new biosimilars product development.

    Topic biosimilars

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Celltrion Will Trial COVID-19 Antiviral From July

    Celltrion has made progress in finding an effective treatment for COVID-19 by identifying 14 antibodies able to neutralize coronavirus. The company aims to eventually roll out mass production of a therapeutic antibody treatment after starting human trials this July.

    Topic Coronavirus vaccines

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Australian Bodies Set Out Joint Position On Coronavirus

    Australia’s off-patent industry association, the GBMA, and local brand organization Medicines Australia have set out their plans for collaborating on supplying essential medicines amid the coronavirus pandemic.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Coronavirus Puts The Brakes On Mylan-Upjohn Merger

    Mylan and Pfizer’s Upjohn were all set to merge into Viatris by midway through this year, subject to certain approvals, but that will now not happen in that timeframe as the global coronavirus pandemic proves an insurmountable barrier to getting the deal over the line.  

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Australia Relaxes Competition Rules To Facilitate Coronavirus Response

    Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Celltrion Makes Progress On Coronavirus Treatment

    Coronavirus_Elbow_pump

    Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.

    Topic Coronavirus

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Trialtrove: 医療用医薬品の臨床試験情報デ...

    COVID-19 Infographic

    COVID-19 Infographic

    Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.

    Topic Coronavirus

医薬品産業専門のジャーナリスト&アナリスト

無料トライアル&お問い合わせ

ニュースサービスでは無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。